Allara Raises $30 Million to Bring AI to Insurance-Covered Women's Healthcare, Taking Total Funding to $75 Million

Allara, a women's health company built around the conditions mainstream medicine has long overlooked, has raised $30 million to expand its care platform and build artificial intelligence tools for clinicians and patients. The round brings the New York-based startup's total funding to $75 million.

Existing investors Index Ventures and GV, Alphabet's venture arm, increased their commitments, while Camino Partners, Foreground and Family Fund joined as new backers. The round, reported on October 13, drew a group of investors led largely by women, a notable detail in a venture market where female founders and women-focused health companies still receive only a small share of capital.

Allara offers integrated care for hormonal, metabolic and reproductive health. It covers conditions including polycystic ovary syndrome (PCOS), thyroid disorders, fertility, postpartum care, metabolic health, perimenopause and endometriosis. The company says it has served more than 120,000 women.

A founder's own story

The company grew out of founder and chief executive Rachel Blank's personal experience. After being diagnosed with PCOS, a common hormonal condition that can affect fertility, metabolism and mental health, she found that the medical support available to her was fragmented and inadequate. She went on to build the kind of care she had been unable to find.

Before launching Allara, Blank worked as an investor at venture firm General Catalyst and then at Ro, the direct-to-consumer telehealth company, where she led its product line for women in menopause. That combination of investment experience and hands-on knowledge of virtual care shaped Allara's model.

"Women shouldn't have to fight for quality healthcare," Blank said. "We're building a company that makes sure they never have to."

Fixing a fragmented system

Allara's data illustrate the frustration that drives many women to the platform. In a survey of more than 1,600 new members, 58% said they had already spoken with two or more providers about their symptoms. Among those who had seen another provider, 80% said clinicians had dismissed or minimised their concerns.

Conditions such as PCOS and endometriosis are notoriously underdiagnosed. Patients often see several doctors over many years before getting a diagnosis, and once diagnosed, they typically need coordinated support from gynaecologists, endocrinologists and nutrition specialists, which traditional healthcare struggles to provide.

Allara's answer is a single, continuous care relationship. Women's health clinicians and registered dietitians work together on each patient's care. Services include GLP-1 medications paired with nutrition guidance, hormone replacement therapy, prescription skincare and hair-loss treatment, and virtual urgent care for issues such as bacterial vaginosis, urinary tract infections and testing for sexually transmitted infections. Most patients are seen the same day or within a week, according to the company.

The approach appears to be producing results. Among members with irregular menstrual cycles, 69% reported improved regularity, Allara says. The company also notes that patients often stay with the platform as their needs change, adding care for new conditions over time.

Built on insurance, not just subscriptions

Unlike many consumer health startups that rely on cash-paying subscribers, Allara is in-network with major insurers in most US states. Its primary revenue comes from insurance reimbursement for visits, supplemented by cash-pay services, prescriptions and supplements. A self-pay option covers women between insurance plans, and its services are eligible for health savings and flexible spending accounts.

That insurance-led model matters. It makes specialist care affordable for a much wider group of women and gives the company a more durable revenue base than one that depends on consumers' willingness to keep paying out of pocket. Allara is also expanding through partnerships with employers and health systems, which could open further channels for growth.

Where AI fits in

A large part of the new funding will go into artificial intelligence. Allara plans to deploy AI tools across the patient journey, from intake to ongoing treatment management. On the provider side, the technology is meant to synthesise patient information, support clinical decision-making and reduce administrative work, a significant burden for clinicians across the US healthcare system. For patients, the company plans AI features in the Allara app to guide women between visits.

Blank has stressed that technology will support clinicians rather than replace them. She argues that human relationships will remain essential, because patients want clinicians who listen and take their concerns seriously, the very thing many of Allara's members say they have not received elsewhere.

The company also plans to use its growing dataset for research in underfunded areas of women's health, including GLP-1 care, endometriosis and long-term pregnancy outcomes. Women's health has historically been under-researched, and data from more than 100,000 patients could make a meaningful contribution.

A strong moment for women-led companies

Allara's round is one of several recent raises in women's health. New York-based Evvy, which offers vaginal microbiome testing, recently closed an oversubscribed $40 million Series B. More broadly, startups with at least one woman founder or co-founder have raised a record amount of venture capital in 2026, according to Dealroom, although the total is heavily skewed by a handful of very large rounds in artificial intelligence. Companies founded solely by women still receive only a small share of funding, which makes rounds like Allara's, led by a female founder and backed largely by women investors, all the more significant.

The bigger picture for women's health

Allara's raise comes amid growing investor interest in women's health, a sector that has historically received a small fraction of healthcare venture funding despite affecting half the population. Investors increasingly recognise that conditions such as PCOS, endometriosis and perimenopause represent large, poorly served markets with clear demand.

The company's priorities over the next six months include broader distribution and strategic partnerships, expanded care offerings, faster AI development and research contributions. Its stated ambition is to become the first place women turn for healthcare.

The story resonates well beyond the United States. Hormonal and metabolic conditions such as PCOS are common among women worldwide, including in India, where awareness is rising but specialist, coordinated care remains hard to access for many. Founders building women's health companies in India and other emerging markets will be watching models like Allara's closely.

For other founders without fresh capital, Blank's advice is pragmatic: "Start with community driven organic growth, it can get you quite far." Allara has built a following of nearly 300,000 across social channels, a reminder that in women's health, trust and community can be as important as technology.